Autopsy report · NCT02843659

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

“Inability to meet protocol objectives”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 9 months before it stopped.
• 45 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Bristol-Myers Squibb

Sponsor type

Industry

Conditions

Sjögren's Syndrome

Interventions

BMS-931699; BMS-986142; Placebo

Participants

45

Sites

34

Countries

Australia, Chile, Colombia, Italy, Mexico, Peru, Poland, Puerto Rico, Russia, South Africa, United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.